NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Price Target & More

$20.32 -0.13 (-0.64 %)

(As of 04/20/2018 02:06 PM ET)

Previous Close$20.45

Today's Range$20.20 - $20.57

52-Week Range$11.85 - $21.00

Volume134,297 shs

Average Volume876,491 shs

Market Capitalization$1.58 billion

P/E Ratio-17.04

Dividend YieldN/A

Beta1.64

About Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:MNTA

CUSIP60877T10

Webwww.momentapharma.com

Phone617-491-9700

Debt

Debt-to-Equity RatioN/A

Current Ratio8.25%

Quick Ratio8.25%

Price-To-Earnings

Trailing P/E Ratio-17.04

Forward P/E Ratio-16.00

P/E GrowthN/A

Sales & Book Value

Annual Sales$138.88 million

Price / Sales11.25

Cash FlowN/A

Price / CashN/A

Book Value$4.90 per share

Price / Book4.15

Profitability

EPS (Most Recent Fiscal Year)($1.20)

Net Income$-88,090,000.00

Net Margins-63.43%

Return on Equity-23.62%

Return on Assets-17.43%

Miscellaneous

Employees279

Outstanding Shares76,860,000

How to Become a New Pot Stock Millionaire

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.12. The biotechnology company earned $64.60 million during the quarter, compared to the consensus estimate of $66.59 million. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The company's revenue for the quarter was up 88.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 EPS. View Momenta Pharmaceuticals' Earnings History.

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Momenta Pharmaceuticals.

What price target have analysts set for MNTA?

8 brokers have issued 1 year price objectives for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $21.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $14.75 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

What are Wall Street analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

1. According to Zacks Investment Research, "Momenta’s third-quarter results were overshadowed by the disappointing results from a phase I study on the proposed biosimilar verison of Orencia. Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics, safety and immunogenicity of M834 to Orencia in normal healthy volunteers. Earlier, Momenta suffered a blow when the FDA approved Mylan’s generic version of Copaxone 40 mg. On the other hand, Momenta’s ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months." (1/2/2018)
2. Cowen Inc analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)

Who are some of Momenta Pharmaceuticals' key competitors?

Some companies that are related to Momenta Pharmaceuticals include Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Repligen (RGEN), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS) and Adaptimmune Therapeutics (ADAP).

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:

Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)
Dr. Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, COO, Chief Scientific Officer & Sr. VP (Age 51)
Mr. Scott M. Storer, Sr. VP, CFO & Principal Accounting Officer
Mr. Bruce A. Leicher J.D., Sr. VP, Gen. Counsel and Corp. Sec. (Age 62)
Dr. Young T. Kwon Ph.D., Sr. VP of Corp. Devel. & Strategy

Has Momenta Pharmaceuticals been receiving favorable news coverage?

Media coverage about MNTA stock has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a news impact score of 0.12 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $20.32.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $1.58 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 675 WEST KENDALL STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]

MarketBeat Community Rating for Momenta Pharmaceuticals (MNTA)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		355 (Vote Outperform)
Underperform Votes:		321 (Vote Underperform)
Total Votes:		676

MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Momenta Pharmaceuticals (NASDAQ:MNTA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Momenta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible downside of 27.41%. The high price target for MNTA is $21.00 and the low price target for MNTA is $6.00. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.00	1.89	1.89
Ratings Breakdown:	1 Sell Rating(s) 6 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$14.75	$14.75	$14.4444	$14.4444
Price Target Upside:	27.41% downside	9.79% downside	2.44% upside	4.67% upside

Momenta Pharmaceuticals (NASDAQ:MNTA) Consensus Price Target History

Price Target History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ:MNTA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/22/2018	Stifel Nicolaus	Upgrade	Hold -> Buy	$18.00 -> $21.00	High
11/1/2017	Cowen	Set Price Target	Hold	$15.00	N/A
10/6/2017	Robert W. Baird	Downgrade	Buy -> Hold	$22.00 -> $15.00	N/A
10/5/2017	JPMorgan Chase	Reiterated Rating	Hold	$14.00	N/A
10/5/2017	Goldman Sachs	Reiterated Rating	Neutral	$18.00 -> $14.00	N/A
10/4/2017	Barclays	Reiterated Rating	Equal Weight	$17.00 -> $16.00	High
8/3/2017	Maxim Group	Set Price Target	Sell	$6.00	Low
5/3/2017	Aegis	Reiterated Rating	Hold	$17.00	Low
2/21/2017	Leerink Swann	Downgrade	Outperform -> Market Perform	$18.00 -> $18.00	N/A
8/5/2016	Brean Capital	Set Price Target	Buy	$19.00	N/A

(Data available from 4/20/2016 forward)

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings History and Estimates Chart

Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.27 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Momenta Pharmaceuticals (NASDAQ MNTA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.41)					N/A
2/21/2018	Q4 2017	$0.06	$0.18	$66.59 million	$64.60 million	View	Listen
11/1/2017	Q3 2017	($0.47)	($0.44)	$29.58 million	$24.09 million	View	N/A
8/2/2017	Q2 2017	($0.50)	($0.50)	$24.64 million	$23.57 million	View	Listen
5/2/2017	Q1 2017	($1.09)	($0.46)	$21.29 million	$26.61 million	View	Listen
2/21/2017	Q416	($0.24)	$0.60	$29.56 million	$34.20 million	View	Listen
11/2/2016	Q316	($0.29)	($0.26)	$25.68 million	$299.14 million	View	N/A
8/4/2016	Q216	($0.34)	($0.31)	$23.55 million	$26.40 million	View	N/A
5/3/2016	Q116	($0.32)	($0.35)	$28.12 million	$19.90 million	View	N/A
2/18/2016	Q415	($0.04)	($0.43)	$30.42 million	$22.40 million	View	Listen
11/4/2015	Q315	($0.19)	($0.44)	$31.76 million	$13.80 million	View	Listen
8/4/2015	Q215	($0.39)	($0.04)	$23.59 million	$44.90 million	View	Listen
5/1/2015	Q115	($0.48)	($0.40)	$11.70 million	$8.60 million	View	N/A
2/17/2015	Q414	($0.16)	($0.31)	$23.80 million	$21.18 million	View	Listen
11/5/2014	Q314	($0.43)	($0.56)	$13.00 million	$9.34 million	View	Listen
7/31/2014	Q214	($0.49)	($0.51)	$11.22 million	$11.00 million	View	Listen
5/6/2014	Q1	($0.55)	($0.53)	$8.41 million	$10.79 million	View	Listen
2/10/2014	Q4	($0.45)	($0.59)	$8.50 million	$12.80 million	View	Listen
11/5/2013	Q313	($0.48)	($0.50)	$8.60 million	$10.80 million	View	N/A
8/1/2013	Q2 2013	($0.45)	($0.57)	$8.85 million	$4.40 million	View	N/A
4/30/2013	Q1 2013	($0.44)	($0.48)	$10.28 million	$7.60 million	View	N/A
2/15/2013	Q4 2012	($0.41)	($0.35)	$10.41 million	$12.70 million	View	N/A
11/7/2012	Q312	($0.27)	($0.51)	$16.48 million	$5.10 million	View	N/A
8/2/2012		($0.17)	($0.20)			View	N/A
5/3/2012		$0.02	($0.10)			View	N/A
2/9/2012		$0.13	($0.02)			View	N/A
11/7/2011		$1.28	$1.18			View	N/A
8/4/2011		$1.21	$1.26			View	N/A
5/5/2011		$0.95	$1.13			View	N/A
2/10/2011		$0.81	$0.77			View	N/A
11/1/2010	Q3 2010	$0.42	$0.70			View	N/A
8/2/2010	Q2 2010	($0.35)	($0.34)			View	N/A
5/6/2010	Q1 2010	($0.34)	($0.37)			View	N/A
2/11/2010	Q4 2009	($0.35)	($0.34)			View	N/A
11/5/2009	Q3 2009	($0.40)	($0.38)			View	N/A
8/6/2009	Q2 2009	($0.44)	($0.43)			View	N/A
5/7/2009	Q1 2009	($0.47)	($0.46)			View	N/A
2/12/2009	Q4 2008	($0.44)	($0.50)			View	N/A
11/3/2008	Q3 2008	($0.43)	($0.45)			View	N/A
7/24/2008	Q2 2008	($0.43)	($0.42)			View	N/A
5/7/2008	Q1 2008	($0.56)	($0.37)			View	N/A
2/14/2008	Q4 2007	($0.60)	($0.40)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Momenta Pharmaceuticals (NASDAQ:MNTA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 97.64%

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/12/2018	Elizabeth Stoner	Director	Sell	7,714	$20.00	$154,280.00	29,378
4/10/2018	Craig A. Wheeler	CEO	Sell	43,334	$19.00	$823,346.00
4/10/2018	Elizabeth Stoner	Director	Sell	3,399	$19.00	$64,581.00	22,777
3/21/2018	Elizabeth Stoner	Director	Sell	3,399	$19.00	$64,581.00	21,176
2/21/2018	Bruce Leicher	SVP	Sell	728	$15.90	$11,575.20	171,194
2/21/2018	Craig A Wheeler	CEO	Sell	3,938	$16.46	$64,819.48	239,869
2/21/2018	Ganesh Venkataraman Kaundinya	COO	Sell	745	$15.90	$11,845.50	495,686
2/14/2018	Bruce Leicher	SVP	Sell	4,948	$15.22	$75,308.56	176,210
2/14/2018	Craig A Wheeler	CEO	Sell	18,648	$16.14	$300,978.72	258,713
2/14/2018	Ganesh Venkataraman Kaundinya	COO	Sell	4,986	$15.23	$75,936.78	501,031
2/14/2018	Scott M. Storer	CFO	Sell	3,972	$15.16	$60,215.52
2/12/2018	Bruce Leicher	SVP	Sell	309	$16.20	$5,005.80	176,210
2/12/2018	Craig A Wheeler	CEO	Sell	1,773	$16.18	$28,687.14	258,713
2/12/2018	Ganesh Venkataraman Kaundinya	COO	Sell	341	$16.20	$5,524.20	501,031
2/8/2018	Bruce Leicher	SVP	Sell	1,861	$16.00	$29,776.00
2/8/2018	Craig A Wheeler	CEO	Sell	10,406	$15.89	$165,351.34	275,526
2/8/2018	Ganesh Venkataraman Kaundinya	COO	Sell	1,917	$16.00	$30,672.00	492,845
1/30/2018	Elizabeth Stoner	Director	Sell	16,264	$18.00	$292,752.00	32,440
1/2/2018	Craig A Wheeler	CEO	Sell	35,666	$14.11	$503,247.26
12/13/2017	Elizabeth Stoner	Director	Sell	5,500	$13.10	$72,050.00	13,240
11/21/2017	Bruce Leicher	SVP	Sell	803	$13.15	$10,559.45	172,906
11/21/2017	Craig A. Wheeler	CEO	Sell	4,116	$13.35	$54,948.60
11/21/2017	Ganesh Venkataraman Kaundinya	COO	Sell	821	$13.15	$10,796.15	487,633
11/10/2017	Bruce Leicher	SVP	Sell	355	$13.07	$4,639.85	173,322
11/10/2017	Craig A Wheeler	CEO	Sell	1,852	$13.25	$24,539.00	258,602
11/10/2017	Ganesh Venkataraman Kaundinya	COO	Sell	392	$13.12	$5,143.04	488,029
9/28/2017	Craig A Wheeler	President	Sell	35,667	$19.03	$678,743.01	286,121
9/1/2017	Craig A. Wheeler	President	Sell	20,367	$17.00	$346,239.00
8/21/2017	Bruce Leicher	SVP	Sell	802	$15.20	$12,190.40	174,064
8/21/2017	Craig A Wheeler	President	Sell	4,116	$15.07	$62,028.12	269,231
8/21/2017	Ganesh Venkataraman Kaundinya	VP	Sell	821	$15.20	$12,479.20	488,846
8/10/2017	Bruce Leicher	SVP	Sell	350	$16.60	$5,810.00
8/10/2017	Craig A. Wheeler	President	Sell	16,953	$16.94	$287,183.82
8/10/2017	Ganesh Venkataraman Kaundinya	VP	Sell	387	$16.60	$6,424.20	489,242
8/2/2017	Craig A Wheeler	President	Sell	200	$17.00	$3,400.00	279,961
5/22/2017	Bruce Leicher	SVP	Sell	859	$14.80	$12,713.20
5/19/2017	Craig A Wheeler	President	Sell	4,116	$15.83	$65,156.28	281,919
5/19/2017	Ganesh Venkataraman Kaundinya	VP	Sell	821	$15.90	$13,053.90
5/10/2017	Bruce Leicher	SVP	Sell	347	$16.00	$5,552.00	175,205
5/10/2017	Craig A. Wheeler	President	Sell	1,852	$15.77	$29,206.04
5/10/2017	Ganesh Venkataraman Kaundinya	VP	Sell	384	$16.00	$6,144.00	490,453
12/15/2016	Richard P Shea	CFO	Sell	9,799	$15.00	$146,985.00	121,972
12/9/2016	Richard P Shea	CFO	Sell	1,451	$15.00	$21,765.00	129,705
11/22/2016	Bruce Leicher	SVP	Sell	1,030	$13.66	$14,069.80
11/22/2016	Craig A. Wheeler	President	Sell	5,880	$13.68	$80,438.40
11/22/2016	James M Roach	VP	Sell	1,091	$13.67	$14,913.97	156,056
11/22/2016	Richard P Shea	CFO	Sell	971	$13.67	$13,273.57	131,731
8/22/2016	Bruce Leicher	SVP	Sell	1,030	$12.05	$12,411.50	183,566
8/22/2016	Craig A. Wheeler	President	Sell	5,880	$12.02	$70,677.60
8/22/2016	James M Roach	VP	Sell	1,091	$12.05	$13,146.55	157,147
8/22/2016	Richard P Shea	CFO	Sell	972	$12.05	$11,712.60	132,703
5/20/2016	Bruce Leicher	SVP	Sell	1,000	$10.40	$10,400.00	184,576
5/20/2016	Craig A Wheeler	President	Sell	5,880	$10.18	$59,858.40	349,521
5/20/2016	Ganesh Venkataraman Kaundinya	VP	Sell	1,050	$10.18	$10,689.00	456,765
5/20/2016	Richard P Shea	CFO	Sell	973	$10.18	$9,905.14	133,675
5/19/2016	John E Bishop	VP	Sell	784	$10.20	$7,996.80	157,640
4/19/2016	John E Bishop	VP	Sell	2,843	$9.57	$27,207.51	160,880
2/23/2016	John E Bishop	VP	Sell	329	$9.70	$3,191.30	107,188
2/22/2016	Bruce Leicher	SVP	Sell	227	$9.65	$2,190.55	131,188
2/22/2016	Craig A Wheeler	President	Sell	1,688	$9.95	$16,795.60	244,342
2/22/2016	John E Bishop	VP	Sell	2,848	$9.66	$27,511.68	109,859
2/19/2016	Bruce Leicher	SVP	Sell	2,000	$9.64	$19,280.00	132,991
2/19/2016	Craig A Wheeler	President	Sell	9,844	$9.37	$92,238.28	253,905
2/19/2016	John E. Bishop	VP	Sell	357	$10.28	$3,669.96	110,263
2/19/2016	Richard P Shea	CFO	Sell	1,823	$9.64	$17,573.72	141,924
2/18/2016	Bruce Leicher	SVP	Sell	337	$10.49	$3,535.13	133,415
2/18/2016	James M Roach	VP	Sell	272	$10.49	$2,853.28	107,269
2/18/2016	Richard P Shea	CFO	Sell	183	$10.49	$1,919.67	142,328
2/17/2016	Craig A Wheeler	President	Sell	1,688	$11.30	$19,074.40	255,874
12/11/2015	Michael Franken	Insider	Sell	520	$15.84	$8,236.80	37,968
11/20/2015	Craig A Wheeler	President	Sell	1,766	$17.86	$31,540.76	200,844
11/19/2015	Craig A Wheeler	President	Sell	2,061	$18.05	$37,201.05	202,610
11/17/2015	Craig A Wheeler	President	Sell	1,766	$17.70	$31,258.20	204,671
11/5/2015	Craig A. Wheeler	President	Sell	51,667	$18.00	$930,006.00	206,437
8/20/2015	Craig A Wheeler	President	Sell	1,766	$22.28	$39,346.48	212,719
8/19/2015	Craig A Wheeler	President	Sell	2,061	$22.02	$45,383.22	214,485
8/19/2015	James M. Roach	VP	Sell	7,011	$22.09	$154,872.99	92,079
8/18/2015	James M Roach	VP	Sell	6,812	$21.80	$148,501.60
8/17/2015	Craig A Wheeler	President	Sell	1,766	$21.77	$38,445.82	216,546
7/15/2015	Elizabeth Stoner	Director	Sell	4,570	$22.35	$102,139.50
6/19/2015	John E Bishop	VP	Sell	21,274	$25.50	$542,487.00
6/18/2015	Bruce Leicher	SVP	Sell	20,000	$23.00	$460,000.00
6/18/2015	Craig A Wheeler	President	Sell	155,000	$24.20	$3,751,000.00
6/18/2015	John E Bishop	VP	Sell	36,313	$23.58	$856,260.54
6/4/2015	Craig A Wheeler	President	Sell	103,333	$22.00	$2,273,326.00
6/1/2015	Bruce Leicher	SVP	Sell	40,000	$21.00	$840,000.00
6/1/2015	James M Roach	VP	Sell	25,000	$21.70	$542,500.00
5/20/2015	Craig A Wheeler	President	Sell	1,766	$19.68	$34,754.88
5/19/2015	Craig A Wheeler	President	Sell	2,061	$19.67	$40,539.87
4/23/2015	Craig A Wheeler	President	Sell	51,667	$20.00	$1,033,340.00
4/23/2015	Ganesh Venkataraman Kaundinya	VP	Sell	34,000	$19.95	$678,300.00
4/20/2015	Craig A Wheeler	President	Sell	6,269	$18.75	$117,543.75
4/17/2015	Bruce Leicher	SVP	Sell	52,910	$19.52	$1,032,803.20
4/16/2015	James M Roach	VP	Sell	50,000	$18.70	$935,000.00
3/16/2015	Richard P Shea	CFO	Sell	23,093	$15.10	$348,704.30
3/5/2015	Richard P Shea	CFO	Sell	23,364	$14.90	$348,123.60
2/24/2015	Craig A Wheeler	President	Sell	2,110	$13.52	$28,527.20
2/20/2015	Bruce Leicher	SVP	Sell	1,891	$12.97	$24,526.27
2/20/2015	Craig A Wheeler	President	Sell	9,563	$13.49	$129,004.87
2/20/2015	John E Bishop	VP	Sell	1,768	$12.97	$22,930.96
2/20/2015	Richard P Shea	CFO	Sell	1,812	$12.97	$23,501.64
2/18/2015	Craig A Wheeler	President	Sell	1,688	$11.91	$20,104.08
12/15/2014	Bennett M Shapiro	Director	Sell	5,800	$12.19	$70,702.00
12/11/2014	Michael Franken	Insider	Sell	2,047	$12.29	$25,157.63
12/1/2014	Bennett M Shapiro	Director	Sell	9,903	$12.00	$118,836.00
11/28/2014	Bennett M Shapiro	Director	Sell	1,897	$12.00	$22,764.00
11/25/2014	Craig A Wheeler	President	Sell	2,210	$11.59	$25,613.90
11/20/2014	Craig A Wheeler	President	Sell	1,768	$11.10	$19,624.80
11/17/2014	Craig A Wheeler	President	Sell	1,768	$10.58	$18,705.44
10/3/2014	Bennett M Shapiro	Director	Sell	3,723	$12.00	$44,676.00
9/12/2014	Peter Barton Hutt	Director	Sell	3,640	$11.42	$41,568.80
8/25/2014	Craig A Wheeler	President	Sell	2,209	$11.45	$25,293.05
8/20/2014	Craig A Wheeler	President	Sell	1,768	$11.54	$20,402.72
8/15/2014	Bennett M Shapiro	Director	Sell	3,722	$12.00	$44,664.00
8/15/2014	Craig A Wheeler	President	Sell	1,768	$11.75	$20,774.00
8/13/2014	Bennett M Shapiro	Director	Sell	3,721	$12.00	$44,652.00
5/23/2014	Craig A Wheeler	President	Sell	2,110	$12.06	$25,446.60
5/20/2014	Craig Wheeler	President	Sell	1,688	$12.08	$20,391.04	376,164
5/15/2014	Craig Wheeler	President	Sell	1,687	$11.09	$18,708.83	377,852
2/25/2014	Craig Wheeler	President	Sell	2,109	$17.47	$36,844.23	379,539
2/24/2014	John Bishop	VP	Sell	1,038	$17.67	$18,341.46	111,621
2/19/2014	Craig Wheeler	President	Sell	3,797	$17.90	$67,966.30	388,398
2/12/2014	Ganesh Venkataraman Kaundinya	VP	Sell	33,000	$17.96	$592,680.00	346,129
1/9/2014	John Bishop	VP	Sell	27,159	$19.50	$529,600.50	93,780
11/25/2013	Bruce Leicher	SVP	Sell	13,492	$18.00	$242,856.00	108,975
11/25/2013	Craig Wheeler	President	Sell	2,215	$17.77	$39,360.55	322,195
11/25/2013	Ganesh Venkataraman Kaundinya	VP	Sell	33,211	$18.02	$598,462.22	391,129
11/19/2013	Craig Wheeler	President	Sell	2,215	$17.17	$38,031.55	324,410
11/15/2013	Craig Wheeler	President	Sell	1,772	$16.88	$29,911.36	326,625
10/11/2013	John Bishop	VP	Sell	5,247	$15.46	$81,118.62	94,618
8/23/2013	Craig Wheeler	President	Sell	2,109	$14.90	$31,424.10	328,397
8/20/2013	Craig Wheeler	President	Sell	2,109	$14.47	$30,517.23	330,506
8/15/2013	Craig Wheeler	President	Sell	1,688	$15.43	$26,045.84	332,615
7/26/2013	Richard P Shea	CFO	Sell	30,000	$16.61	$498,300.00
6/27/2013	Richard P Shea	CFO	Sell	10,522	$14.61	$153,726.42
6/19/2013	Richard P Shea	CFO	Sell	21,550	$14.61	$314,845.50
5/23/2013	Craig A Wheeler	President	Sell	2,109	$13.03	$27,480.27
5/21/2013	Craig A Wheeler	President	Sell	2,109	$12.83	$27,058.47
5/15/2013	Craig A Wheeler	President	Sell	1,687	$13.33	$22,487.71
3/5/2013	Elizabeth Stoner	Director	Sell	2,040	$14.00	$28,560.00
2/15/2013	Bruce Leicher	SVP	Sell	1,040	$12.26	$12,750.40

(Data available from 1/1/2013 forward)

Momenta Pharmaceuticals (NASDAQ MNTA) News Headlines

Source:

Date	Headline
	Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 18 at 9:40 AM
	Momenta Pharmaceuticals (MNTA) Rating Reiterated by Stifel Nicolaus www.americanbankingnews.com - April 13 at 9:27 PM
	Maxim Group Reiterates $6.00 Price Target for Momenta Pharmaceuticals (MNTA) www.americanbankingnews.com - April 13 at 7:15 PM
	Elizabeth Stoner Sells 7,714 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock www.americanbankingnews.com - April 13 at 7:11 PM
	Momenta Pharmaceuticals, Inc. (MNTA) Director Sells $64,581.00 in Stock www.americanbankingnews.com - April 12 at 7:35 PM
	Elizabeth Stoner Sells 3,399 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock www.americanbankingnews.com - April 12 at 7:35 PM
	Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $823,346.00 in Stock www.americanbankingnews.com - April 12 at 7:17 PM
	Momenta Pharmaceuticals' (MNTA) Hold Rating Reiterated at Stifel Nicolaus www.americanbankingnews.com - April 8 at 12:40 AM
	Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 5 at 12:31 AM
	Momenta Pharmaceuticals (MNTA) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 3 at 11:31 PM
	Momenta Pharmaceuticals (MNTA) Given a $15.00 Price Target at Cowen www.americanbankingnews.com - April 2 at 4:16 PM
	How Did Sandoz Perform in 4Q17 and Fiscal 2017? finance.yahoo.com - April 2 at 9:57 AM
	Momenta Pharmaceuticals (MNTA) Upgraded by BidaskClub to Buy www.americanbankingnews.com - March 30 at 2:19 PM
	Analyzing Momenta Pharmaceuticals (MNTA) and Gemphire Therapeutics (GEMP) www.americanbankingnews.com - March 29 at 11:06 PM
	Momenta Pharmaceuticals (MNTA) Rating Lowered to Hold at BidaskClub www.americanbankingnews.com - March 27 at 4:34 PM
	Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClub www.americanbankingnews.com - March 27 at 3:28 PM
	Momenta Pharmaceuticals, Inc. (MNTA) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - March 24 at 9:56 AM
	Sectoral Asset Management Inc Grows Stake in Momenta Pharmaceuticals, Inc. (MNTA) www.americanbankingnews.com - March 5 at 3:35 PM
	Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences finance.yahoo.com - March 5 at 9:44 AM
	Reviewing Global Blood Therapeutics (GBT) and Momenta Pharmaceuticals (MNTA) www.americanbankingnews.com - March 5 at 3:08 AM
	Momenta Pharmaceuticals, Inc. (MNTA) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - February 27 at 12:32 PM
	Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - February 26 at 4:57 PM
	Momenta Pharmaceuticals (MNTA) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - February 25 at 4:54 PM
	Momenta Pharmaceuticals (MNTA) Upgraded to "Buy" by Stifel Nicolaus www.americanbankingnews.com - February 25 at 2:06 PM
	Momenta Pharmaceuticals (MNTA) Upgraded to "Hold" by ValuEngine www.americanbankingnews.com - February 25 at 12:34 AM
	KBC Group NV Boosts Stake in Momenta Pharmaceuticals, Inc. (MNTA) www.americanbankingnews.com - February 24 at 5:24 AM
	Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $11,575.20 in Stock www.americanbankingnews.com - February 23 at 3:40 PM
	Momenta Pharmaceuticals, Inc. (MNTA) COO Ganesh Venkataraman Kaundinya Sells 745 Shares www.americanbankingnews.com - February 23 at 3:40 PM
	Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 3,938 Shares www.americanbankingnews.com - February 23 at 3:22 PM
	Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy finance.yahoo.com - February 23 at 9:25 AM
	Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4 finance.yahoo.com - February 22 at 4:49 PM
	Momenta Pharmaceuticals Wraps Up a Bleak Year finance.yahoo.com - February 22 at 4:49 PM
	Today’s Research Reports on Stocks to Watch: Momenta Pharmaceuticals and Nektar Therapeutics finance.yahoo.com - February 22 at 9:18 AM
	Teva's Problems Continue to Mount With No Relief in Sight www.msn.com - February 21 at 4:40 PM
	Momenta Pharmaceuticals (MNTA) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS www.americanbankingnews.com - February 21 at 11:24 AM
	Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update finance.yahoo.com - February 21 at 9:35 AM
	Momenta Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - February 21 at 9:35 AM
	Momenta posts 4Q profit finance.yahoo.com - February 21 at 9:35 AM
	BidaskClub Upgrades Momenta Pharmaceuticals (MNTA) to Buy www.americanbankingnews.com - February 19 at 4:02 PM
	Biohaven Pharmaceutical (BHVN) versus Momenta Pharmaceuticals (MNTA) Head to Head Survey www.americanbankingnews.com - February 17 at 12:34 PM
	Momenta Pharmaceuticals, Inc. (MNTA) CFO Scott M. Storer Sells 3,972 Shares www.americanbankingnews.com - February 14 at 10:18 PM
	Craig A. Wheeler Sells 1,773 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock www.americanbankingnews.com - February 14 at 10:18 PM
	Momenta Pharmaceuticals, Inc. (MNTA) COO Sells $75,936.78 in Stock www.americanbankingnews.com - February 14 at 9:58 PM
	Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $75,308.56 in Stock www.americanbankingnews.com - February 14 at 9:58 PM
	Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $300,978.72 in Stock www.americanbankingnews.com - February 14 at 9:40 PM
	Teva Pharmaceutical Industries Ltd -- Moody's says launch of second generic version of Copaxone 40mg is credit negative for Teva finance.yahoo.com - February 13 at 4:27 PM
	Ganesh Venkataraman Kaundinya Sells 1,917 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock www.americanbankingnews.com - February 12 at 7:08 PM
	Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $29,776.00 in Stock www.americanbankingnews.com - February 12 at 7:08 PM
	Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 10,406 Shares www.americanbankingnews.com - February 12 at 6:46 PM
	Momenta Pharmaceuticals (MNTA) to Release Quarterly Earnings on Monday www.americanbankingnews.com - February 12 at 3:22 AM

Momenta Pharmaceuticals (NASDAQ:MNTA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Momenta Pharmaceuticals (NASDAQ:MNTA) Income Statement, Balance Sheet and Cash Flow Statement

Momenta Pharmaceuticals (NASDAQ MNTA) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff